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Abstract
Background: Encoded by the var gene family, highly variable Plasmodium falciparum erythrocyte membrane
protein-1 (PfEMP1) proteins mediate tissue-specific cytoadherence of infected erythrocytes, resulting in immune
evasion and severe malaria disease. Sequencing and assembling the 40–60 var gene complement for individual
infections has been notoriously difficult, impeding molecular epidemiological studies and the assessment of
particular var elements as subunit vaccine candidates.
Methods: We developed and validated a novel algorithm, Exon-Targeted Hybrid Assembly (ETHA), to perform
targeted assembly of var gene sequences, based on a combination of Pacific Biosciences and Illumina data.
Results: Using ETHA, we characterized the repertoire of var genes in 12 samples from uncomplicated malaria
infections in children from a single Malian village and showed them to be as genetically diverse as vars from
isolates from around the globe. The gene var2csa, a member of the var family associated with placental malaria
pathogenesis, was present in each genome, as were vars previously associated with severe malaria.
Conclusion: ETHA, a tool to discover novel var sequences from clinical samples, will aid the understanding of
malaria pathogenesis and inform the design of malaria vaccines based on PfEMP1.
ETHA is available at: https://sourceforge.net/projects/etha/.
Keywords: Malaria, Plasmodium falciparum, Plasmodium falciparum erythrocyte membrane protein-1, PfEMP1, var,
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Background
Naturally acquired immunity to malaria appears to
occur, at least in part, through the acquisition of anti-
bodies to parasite antigens expressed on the surface of
infected erythrocytes. In epidemiological studies, having
antibodies to these parasite-produced erythrocyte sur-
face antigens is consistently associated with protection
against clinical malaria [1, 2]. The best studied of these
variant surface antigen (VSA) families, Plasmodium
falciparum erythrocyte membrane protein-1 (PfEMP1)
antigens, are large molecules expressed on the surface of
the infected erythrocyte [3, 4] that bind to endothelial
receptors [5–8]. Each PfEMP1 typically contains be-
tween two and eight Duffy-binding-like (DBL) domains
and one to two cysteine-rich interdomain regions
(CIDR). PfEMP1s are encoded by the var family of
genes, 40 to 61 of which have been found in the few P.
falciparum assembled genomes available to date. An in-
fected erythrocyte expresses only one PfEMP1 variant
on its surface [9]. P. falciparum parasites undergo clonal
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the host immune response [10]. PfEMP1s mediate
tissue-specific cytoadherence, which allows infected
erythrocytes to sequester in small capillaries of targeted
host tissue and evade clearance by the spleen, thereby
producing devastating pathologic effects [11]. Compared
to other P. falciparum genes, most var genes exhibit ex-
treme diversity, with less than 50% shared amino acid
sequence identity [12]. Such diversity has proven a major
obstacle to the development of strategies to amplify and
sequence new var genes from clinical samples, hamper-
ing the understanding of var gene biology and the role
of PfEMP1 in clinical disease. The full complement of
var genes is only known for a few reference genomes
and two clinical samples [13]. Until now, it has thus not
been possible to sequence vars with adequate complete-
ness and from a number of samples sufficient to associ-
ate specific var elements with clinical outcomes such as
pregnancy-associated or severe malaria [14].
The best characterized PfEMP1, VAR2CSA, is expressed
on the surface of infected erythrocytes that bind to chon-
droitin sulfate in the placental matrix [15, 16]. Antibodies
to this antigen prevent placental cytoadherence and are as-
sociated with protection from placental malaria [15]. From
the limited number of variants sequenced, VAR2CSA ex-
hibits significantly greater sequence conservation than
other vars, with over 75% shared amino acid identity
among orthologs [12, 17, 18], making it a promising sub-
unit vaccine candidate against pregnancy-associated mal-
aria. Better characterization of VAR2CSA diversity within
and across different geographic locations would enable an
informed assessment of the need for regionally-based vac-
cines versus a globally effective vaccine approach.
The study of rapidly evolving genes such as those that
encode most variant surface antigen families relies on de
novo genome assemblies and/or gene-targeted sequen-
cing approaches. Assessment of genetic variation based
on mapping of re-sequencing reads requires reads to
map uniquely between isolates within a maximum se-
quence divergence cutoff (usually ~2%, or a maximum
of two to three single nucleotide polymorphisms, SNPs,
in a 100 bp read). A large proportion of reads originating
from var loci often cannot be reliably mapped across
isolates, either because they map to repetitive regions
present in multiple copies in the genome or because
they differ among orthologous copies by more than the
threshold cutoff necessary for mapping [19]. The long
sequence reads generated with Pacific Biosciences (Pac-
Bio) technology have great utility as they allow the
placement of repetitive regions in an assembly, using
flanking unique conserved sequences as a genomic an-
chor [20, 21]. However, if the PacBio reads are short in
comparison to the length of VSA genes, the high error
rate of PacBio-generated sequences, which can top 15%,
may lead to assembly errors, including chimeras among
members of multigene families. In contrast, Illumina se-
quencing technologies produce much more accurate data,
but the short read length poses a challenge for var gene
assembly.
Here, we describe a novel, specialized pipeline that
leverages publicly available var gene sequences and
capitalizes on a combination of relatively low amounts
of PacBio and Illumina data to reconstruct var gene se-
quences present in clinical malaria field samples. We
show that all P. falciparum genomes from uncompli-
cated malaria infections harbor var2csa and also var
gene subclasses previously associated with severe mal-
aria. We also show a lack of clustering of VAR2CSA by
geography and identify segments conserved across most
var2csa sequences despite high overall sequence diver-
sity at this locus among all samples analyzed. Such
segments, if immunogenic, suggest the potential of a
pregnancy-associated malaria vaccine based on a limited
number of strains.
Methods
Sample collection, genomic DNA preparation, and
quantification of host contamination
A total of 3–5 mL of venous whole blood were obtained
from 12 children with symptomatic malaria episodes in
Bandiagara, Mali, in 2010, as part of a study measuring
the incidence of malaria at a vaccine testing site [22].
Whole blood samples were leukocyte-depleted at the
time of collection using CF11 columns [23] and then
kept frozen at –80 °C until DNA extraction. DNA was
extracted using the QIAamp Blood Midi kit, yielding
300 μL of each sample eluted in distilled water. Samples
were stored at –80 °C until DNA sequencing. We deter-
mined clonality using six neutral microsatellite markers
[24, 25]. Host contamination was calculated retrospect-
ively by measuring the proportion of sequenced reads
that mapped to the human genome (version GRCh37)
(see below). Isolate NF54 was provided by Sanaria,
Working Cell Bank SAN02-073009, cultured using
standard protocols [26], and DNA extracted as above.
Generation of Illumina and PacBio whole-genome
sequence data and genome assemblies
Genomic DNA libraries for all samples were constructed
for sequencing on the Illumina platform using the KAPA
Library Preparation Kit (Kapa Biosystems, Woburn, MA,
USA). First, 500 ng of DNA was fragmented with the
Covaris E210 to about 200 bp. Then libraries were pre-
pared using a modified version of manufacturer’s proto-
col. The DNA was purified between enzymatic reactions
and the size selection of the library was performed
with AMPure XT beads (Beckman Coulter Genomics,
Danvers, MA, USA). The polymerase chain reaction
(PCR) amplification step was performed with primers
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containing an index sequence six nucleotides in length. Li-
braries were assessed for concentration and fragment size
using the DNA High Sensitivity Assay on the LabChip GX
(Perkin Elmer, Waltham, MA, USA). The library con-
centrations were also assessed by quantitative PCR
using the KAPA Library Quantification Kit (Complete,
Universal) (Kapa Biosystems, Woburn, MA, USA). The
libraries were pooled and sequenced on a 100 bp,
paired-end, Illumina HiSeq 2500 run (Illumina, San
Diego, CA, USA).
For the Malian clinical samples, DNA was prepared
for PacBio sequencing using the DNA Template Prep
Kit 2.0 (Pacific Biosciences, Menlo Park, CA, USA).
First, DNA was fragmented with the Covaris E210 to
generate fragments ~3, 8, or 10 kb in length. Libraries
were then prepared per the manufacturer’s protocol.
Three SMRT cells were sequenced per library, using
P4C2 chemistry and a 120-min movie on the PacBio RS
II (Pacific Biosystems, Menlo Park, CA, USA). The
process for the generation of NF54 PacBio data was
slightly different; NF54 had a longer insert library size
(18,800 bp) and was sequenced using P6-C4 chemistry.
Two assemblies were generated for each sample using
PacBio-only sequencing data or PacBio plus Illumina
data. PacBio-only assemblies were created with Sprai
using default settings (http://zombie.cb.k.u-tokyo.ac.jp/
sprai/index.html); Sprai by default does not use reads
shorter than 2000 bp. Hybrid assemblies using both
PacBio and Illumina data were created with Celera as-
sembler, with default settings [27].
Extraction of var gene-like sequences from whole-genome
assemblies
Sequences resembling var exon 1 were extracted from
the whole-genome assemblies by stitching together leni-
ent amino acid-level alignments to known reference var
genes. Amino acid alignments were generated using
PROmer (promer –maxmatch) [28] between each whole-
genome assembly and the full set of known exon 1 se-
quences from 3D7 and VarDom [13]). Matches of at
least 50% identity at least 100 bp long were grouped to-
gether when they were no more than 100 bp apart, and
any such group with a total length of at least 2000 bp
was considered a candidate exon 1 sequence. These can-
didate sequences were then oriented according to the
reading frame with the least number of stop codons. Fi-
nally, duplicates and subsequences were eliminated by
removing any sequence that was covered to at least 90%
(proportion of length × proportion of identity) by another.
Algorithm for var gene reconstruction using ETHA
Likely ends (500 bp) of var exon 1 sequences were iden-
tified in each PacBio assembly by aligning known exon 1
ends from all var genes available in the VarDom
database, including the var genes from the reference
3D7 genome, against each assembly, using NUCmer with
option maxmatch [28]. Regions of the assembly from
the start of each such match to 100 bp past the inferred
end of exon 1 were extracted from the assembly and
then kmer-corrected, using all 71mers observed at
least ten times in the Illumina data. These repaired
sequences were re-aligned to the reference exon 1 ends,
the exact end identified as the rightmost AAGGT occur-
ring in the rightmost 100 bp of the match, and the 71mer
ending with that AAGGT was added to the set of identi-
fied exon 1 end kmers. A similar approach was used for
some other variants including ACCTT (the reverse com-
plement of AAGGT) and other 5mers occurring with low
frequency at the end of var exon 1. This set of splice site-
containing 71mers was then used to start a leftward kmer
walk. This iteratively follows each 71mer with a new
71mer which overlaps the previous exactly over 70 shared
base pairs, extending it by one base pair.
This process is followed iteratively until no overlap-
ping kmers are found (with an occurrence count of at
least ten) or a stop codon is encountered in all reading
frames. Kmers at the left-most end of an open reading
frame are collected as the starting point for a rightward
walk following the same method, with the added stop-
ping condition that a walk will end as soon as a kmer is
seen which was in the original set of splice site-
containing kmers. These rightward walks are used to
identify further splice site kmers by finding the right-
most kmer ending in AAGGT, in each kmer walk termi-
nated by the end of all reading frames. These new
splice-site kmers are added to the original set and the
leftward walk is repeated, this time using the seeds of
the rightward walk as an additional stopping condition.
All of the kmers encountered in this final leftward walk
are saved as the set of possible 71mers belonging to
exon 1. A final leftward walk is carried out to generate
all possible sequences that start with the most recent set
of splice-site kmers, using only the exon 1 71mers.
These sequences are filtered to remove any that is
shorter than 1 Kb and the resulting set forms the candi-
date exon 1 sequences. These candidate exon 1 se-
quences are aligned to the whole-genome assembly and
segments are extracted of at least 500 bp aligning at least
90% identity. The extracted sequences are then assem-
bled using a simple unitigger which requires perfectly
matching overlaps.
We then identify all sequences formed by a unique path
from the starting kmer and add them to the final set of
exon 1 sequences if not already present. Duplicates,
defined as sequences fully contained within any exon 1
unitigs, are removed. Also removed are sequences which
are completely covered by another sequence with which
they share ≥ 95% sequence identity.
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NF54 validation
An optimal NF54 PacBio-only assembly was constructed
from all PacBio data using PacBio’s Hierarchical Genome
Assembly Process (HGAP) [29]. A second, sub-standard
assembly that matched features of the 12 Malian clinical
samples was generated from reads subsampled from the
total NF54 PacBio data to match the lower median read
length and read number of the datasets for Malian
clinical samples. This simulated clinical assembly was
created with HGAP using the subset of PacBio reads
with the whitelist option within SMRT Analysis (v2.3).
71mers used for kmer walk by ETHA were extracted
from NF54 Illumina data. The original standard bio-
informatic approach and ETHA were then run on this
assembly to pull extracted and to generate reconstructed
exon 1 sequences, respectively, as described above. For
both extracted and reconstructed NF54 output, exon 1
sequences were then compared to the complete set of
known exon 1 sequences from the reference 3D7 by
alignment using Mummer [28] and coverage and percent
identity was calculated for the single best match from
the ETHA output to each reference 3D7 exon 1 se-
quence with custom scripts.
Amplification and structural annotation of var2csa
sequences from genomic DNA
Primers flanking var2csa, based on its upstream pro-
moter sequence (UPSE; ~500 bp upstream of translation
start site) and on the acidic terminal sequence (ATS), were
designed using sequences from GenBank (accession
numbers: EF614224; EF614233; EF614230; EF614227;
EF614231; EF614225; EF614226; EF614229; EF614232;
EF614228) and VarDom (clones 3D7, HB3, DD2, IT4/
FCR3, PFCLIN, RAJ116, IGH). UPSE sequences were pro-
vided by Thomas Lavstsen [13]. A single PCR was per-
formed using PacBio 96-plex 21 bp padded barcode mode
according to manufacturer’s instructions. A target specific
forward primer Frag1_ExF (5’-GTGATGTATGTGTTTA
TGGAATAACTAGC-3’) and a target specific reverse pri-
mer R_IT4var04_ATS (5’-TCCTTACGTTCCATATTCCA
CACTTC-3’) were used. The cycling conditions were as
follows: a 50 μL reaction containing 5 μL of 10X LA PCR
buffer, 8 μL of dNTPs (2.5 mM each), 5 μL of each the for-
ward and reverse primer (1 μM), 0.5 μL of TaKaRa LA
Taq (5 units/μL), and 2 μL of DNA sample. Cycling condi-
tions included an initial denaturation step of 2 min at
94 °C, followed by 10 s at 98 °C denaturation, 10 min an-
nealing and elongation step at 60 °C, with 35 cycles
followed by a final elongation step of 10 min at 72 °C. Suc-
cessful PCR products of 10 kb from each sample were
purified and pooled in equimolar concentrations. The
pooled amplicons were sequenced using a Single Molecule
Real Time (SMRT) RS II amplicon sequencing protocol
using P6C4 chemistry, and assembled with SMRT analysis
v2.3 ConsensusTools. The VarDom server was used for
the var gene domain annotation, according to the default
protocol parameters.
Identification of upstream promoter sequence (UPS) for
each var gene in the Malian samples
Regions upstream from the translation start positions of
var genes in our assemblies were extracted for analysis
as follows. First, a set of possible exon 1 sequences was
created from kmers in Illumina reads, as described
above. Then, all PacBio reads were mapped to these se-
quences using NUCmer and the best match for each
PacBio read extracted if it was at least 500 bp long and
matched the reconstructed exon 1 with at least 95% se-
quence identity. The extracted sequences were then as-
sembled in a simple, greedy fashion to create a set of
exon 1 unitigs. Those unitigs containing the starts of
exon 1 sequences were matched using NUCmer against
contigs in the final assembly. The final set of promoter
regions consisted of the assembly regions upstream of
the exon 1 start of each match (up to 2000 bp but as
short as 900 bp if the end of the contig was reached)
plus the first 100 bp of exon 1 coding sequence.
To identify the coordinates of each promoter sequence
in those upstream regions and the UPS class to which
each belonged, a BLAST search was done of known pro-
moter sequences against the var gene upstream se-
quences. Each BLAST hit was then scored to determine
the best hits. The scores were determined by adding the
length, percent identity, and the bit score of the align-
ment (inversely proportional to e-value, and of the same
order of magnitude and the other two parameters). This
scoring takes into account the three factors that most
impact the quality of the BLAST hit. The percent iden-
tity had little impact on the scores, since nearly all of the
hits have a percent identity between 90% and 100%. The
coordinates for all the BLAST hits were inferred from
the alignments. The best hits were defined by keeping
only those hits within 5% of the score of the top hit for
each upstream sequence. The 5% threshold represents a
natural inflection point in the distribution of hit scores
(scores tended to drop off after a few very highly scoring
hits; alternatively, scores declined gradually, but repre-
sented redundant hits, i.e. alternative alignments of the
same promoter to the same target region). All redundant
hits were removed from the set of best hits, such that
only unique best hits remained. Most often this resulted
in only one remaining hit of a “known” promoter against
the upstream region of a var, which defined the UPS
class, and with the alignment coordinates defining the
UPS location. In cases where more than one hit
remained, it was a result of either: (1) partially overlap-
ping hit coordinates from “known” promoters from the
same class; or (2) perfectly overlapping hits, but from
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“known” promoters of different classes. In (1), the final
UPS coordinates were defined by the reunion of all over-
lapping hits. In (2), the UPS coordinates were common
to all hits and the var was assigned to a hybrid class de-
fined by all subject “known” promoters. Finally, a small
number of var sequences appear to have more than one
non-overlapping upstream promoter, although these
could represent assembly artifacts.
Identification of domain cassettes DC8 and DC13
DC8 and DC13 containing sequences were retrieved
from VarDom server. Each DBL and CIDR domain was
identified and aligned separately along with the known
DC8 and DC13. Phylogenetic trees were inferred to
identify sequences that clustered with either DC8 or
DC13 domains. Sequences that contained both DBLα2
and CIDRα1.1 were defined as DC8 whereas those with
DBLα1.7 and CIDRα1.4 were DC13.
Phylogenetic tree and recombination analysis
Multiple sequence alignments were performed with
AQUA [30], a program that optimizes multiple align-
ment using MAFFT and MUSCLE. A maximum likeli-
hood tree was reconstructed with RAxML-PTHREADS
(version 8.2.4) [31], based on the AQUA output. The
gamma model of substitution with rate heterogeneity
was used, together with AUTO option, to determine the
matrix of substitution that best fits the data. JTT and VT
were identified as the best-scoring amino acid substitu-
tion models. The phylogenetic tree was visualized with
interactive Tree of Life (iTOL version 3). To determine
whether var2csa sequences cluster regionally, a multiple
alignment was performed using nucleotide sequences
with MAFFT L-iNS-i default options followed by careful
manual evaluation and editing when required. The align-
ment was used as an input for recombination analysis
using RDP4 version 4.36 [32]. The program detected re-
gions of recombination in the alignment. Therefore, a
Neighbor-Net analysis was performed to reconstruct a
phylogenetic network incorporating recombination events,
using Splitstree version 4.14.4, based on uncorrected
p-distances [33].
Results and discussion
De novo whole-genome assemblies
Genomic DNA (gDNA) was obtained from leukocyte-
depleted blood from each of 12 clinical malaria samples
collected in Bandiagara, a town in Mali, West Africa.
This set included samples with both low (5000–25,000
parasites/μL) and high (>150,000 parasites/μL) parasit-
emia, as well as monoclonal and polyclonal infections
(Additional file 1: Table S1). Illumina and PacBio data
were obtained for all samples (see “Methods”). The insert
size of Illumina libraries was in the range of 316–346 bp
(Additional file 1: Table S2). The 12 samples were multi-
plexed in a single Illumina HiSeq2500 channel and data
generated corresponded to 78X–141X coverage of the P.
falciparum genome per sample. A 3Kb, 8Kb, and/or 10Kb
PacBio insert library was built for each sample (Additional
file 1: Table S2). The total PacBio data, generated through
PacBio’s Single Molecule Real Time (SMRT) sequencing,
was equivalent to 8X–52X coverage, depending on the
sample. The varying amount of data per sample depended
on the percent host contamination, the variation associ-
ated with multiplexing samples in an Illumina run, the
number of PacBio SMRT cells sequenced, and the vari-
ation inherent to each SMRT cell (Additional file 1: Tables
S1 and S2).
Assemblies for the 12 Malian clinical samples were
created using either Celera (PacBio with Illumina) or
Sprai (PacBio-only) assemblers (see “Methods”). In each
case, the assembly considered to be best was selected
based on various combinations of assembly metrics, in-
cluding number of contigs, cumulative length of assem-
bly, length of largest contig, and N50 (the length of the
largest contig in the subset containing the smallest 50%
of all contigs) (Additional file 1: Table S3). The P. fal-
ciparum assemblies generated from the six monoclo-
nal infections were usually < 30 Mb in length, and
consisted of ~450 large contigs (≥10 Kb) of an
average maximum size of 325 Kb. These large contigs
together had an average cumulative length of 22 Mb
(~94% of the reference genome), corresponding to the core,
unique regions of the genome (Fig. 1; Additional file 1:
Table S3). The assemblies of the six polyclonal samples
were all longer than 30 Mb, and the number of large con-
tigs was ~20% greater than those in monoclonal samples,
while the number of small (<10 Kb) contigs from the poly-
clonal samples was roughly twice as big as those from the
monoclonal samples, reflecting the presence of mul-
tiple allelic forms. All assemblies contained at least
500 small contigs of 2–10 Kb. These small contigs
map primarily to telomeric and sub-telomeric regions,
suggesting that they correspond to fragments of re-
peats or the multigene families preferentially located
in these regions (Fig. 1; Additional file 2).
The size of all assemblies was larger than the reference
3D7 P. falciparum genome. This is likely due to two pri-
mary factors. First, the relatively low amount of PacBio
data that could be generated for each clinical sample
were insufficient to correct all internal errors in the
PacBio data. As a result, each assembly likely contains
redundant contigs that could not be merged due to
incorrectly reconstructed nucleotide positions (Fig. 1).
Second, more than one clone was detected in half of
these samples; therefore, some of the redundancy in the
assembly is likely due to nucleotide-level differences in
orthologous regions from multiple parasites. This may
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explain why most assemblies from polyclonal infec-
tions are larger than those from monoclonal infections
(Additional file 1: Table S3).
Extracted var gene exon 1 sequences in de novo whole-
genome assemblies
Currently available P. falciparum genome assemblies
contain 40–61 complete var genes in addition to several
dozen var pseudogenes [34]. These genes are mostly lo-
cated in sub-telomeric regions of the chromosomes, with
a few clusters located in the core region of chromo-
somes 4, 6, 7, 8, and 12 (Fig. 1). Each complete var gene
consists of two exons, the first of which, at 2500–
10,500 bp, is longer and much more variable in length
than the second (1000–1500 bp) [34]. While the PfEMP1
segment derived from exon 2 corresponds mostly to the
inter-membrane and intra-cellular domains of the pro-
tein, exon 1 gives rise to the motifs involved in cytoad-
herence and rosetting, and consequently is of particular
interest in terms of pathogenesis.
To determine the accuracy of these clinically important
exon 1 sequences recovered directly from default assem-
blies with standard bioinformatics approaches, exon 1 se-
quences were extracted from each of the 12 Malian
whole-genome assemblies based on amino acid sequence
similarity to those of existing var exon 1 sequences from
the reference P. falciparum 3D7 (Pf3D7) genome, as well
as others available through the VarDom database [13].
The putative exon 1 sequences extracted were validated as
bona fide var sequences by comparison with the NCBI nr/
nt nucleotide collection. Without exception, each se-
quence was spanned (with or without internal gaps) by at
least one match to a known var, with a bitscore of at least
200. Between 58 to 177 exon 1 sequences were extracted
from each of the 12 Malian sample genome assemblies in
this manner, with a higher number from polyclonal versus
monoclonal samples (Additional file 1: Table S4). As with
Pf3D7 var exon 1 sequences, the median length of ex-
tracted exon 1 sequences in each assembly was ~5 Kb for
most samples, and the length of individual exon 1 se-
quences fell within a wide range of 2 to 10 Kb (Fig. 2).
Several observations suggest the presence of assembly
errors in the var exon 1 sequences extracted directly
from the assemblies of the 12 Malian clinical samples.
First, the number of exon 1 sequences per sample is
much larger than the 40–61 expected. This is most likely
due to the presence of duplicated segments in the as-
sembly, which could not be merged due to incompatible
sequencing errors (see above). Second, some segments
in these extracted var sequences have no equivalent in
the k-mer Illumina data, i.e. they have no identical se-
quence among all the 71mers extracted from all Illumina
reads generated for the same sample. Finally, in these ex-
tracted var sequences with missing k-mer data, no inde-
pendently generated k-mer path (tiling paths of 71mers
extracted from all Illumina reads) unites the two regions
flanking those segments with no k-mer coverage. The
second observation can be explained by poor PacBio
correction, but the final point suggests the presence of
larger structural errors, such as chimeras. Therefore, the
large number of complete exon 1 sequences extracted
directly from these assemblies is inflated by the presence
of chimeras, as well as by duplicated copies.
Reconstruction of var gene exon 1 sequences by a novel
algorithm, ETHA
Compared to Pf3D7, the var exon 1 sequences extracted
directly from each of the 12 genome assemblies were ex-
tremely variable in length and in number. In addition to
the presence of duplicates and chimeras, the length dis-
tribution is skewed toward elements smaller than the
median length, compared with Pf3D7. For this reason,
an algorithm named ETHA was developed to more ac-
curately recover exon 1 sequences (Fig. 3; see
“Methods”). Briefly, Illumina data corresponding to the
var genes is: (1) identified by finding 71 bp segments
containing var splice site sequences in the assembly and
iteratively following possible continuations within the
Illumina data; (2) assembled by generating all possible
paths within de Bruijn graph of 71mers; (3) reconciled
with the whole-genome assembly by choosing paths that
align best with the whole-genome assembly; and (4) as-
sembling reconciled var sequences in a sample and re-
moving duplicates. While the original extraction method
described above was done using the best assemblies,
we found that Celera assemblies (while often superior
Fig. 1 Whole-genome assembly contigs aligned against the 3D7 Reference. Contigs from Sample 303_1 (blue) aligned to chromosome 12 of 3D7
(black); var exon 1 sequences extracted from 303_1 (see “Methods”) and previously identified var exon 1 sequences from 3D7 are labeled as red
dots on the contigs and chromosome. Exon 1 sequences extracted from the whole-genome assembly of 303_1 are found in chromosome regions
similar to where 3D7 exon 1 sequences have been found. While some are found towards the center of the chromosome, a portion are also found
on the ends, where complicated repeat regions and multi-gene families cause assembly issues and assembly contigs are seen to pile up in this
area. Similar layouts for all 14 chromosomes for each of the 12 Malian clinical samples can be found in the Additional files
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as measured by N50 and other assembly metrics)
were less effective than Sprai assemblies as input to
the current pipeline, as measured by coverage of
known reference var genes. Celera Assembler’s double
use of Illumina data may explain this reduced coverage.
Therefore, the Sprai assemblies were used as input
for ETHA.
ETHA reconstructs both complete and partial exon 1
sequences. Those sequences containing a start methio-
nine residue were judged to include the start of an exon;
Fig. 2 Number and length of var exon 1 sequences. a Complete exon 1 sequence extracted from whole-genome assemblies using standard
bioinformatic methods, requiring a minimum sequence length of 2 Kb. b Complete exon 1 sequences reconstructed from whole-genome assemblies
by ETHA. Distributions of var exon 1 lengths in each sample are represented by a box-and-whiskers plot: the median is indicated by a dark line, the
first and third quartiles by the boundaries of the box, and the minimum and maximum, excluding outliers, by the whiskers. Outliers are those points
lying beyond the first or third quartile by more than 1.5 times the interquartile range. Clinical samples are colored by clonality (polyclonal: orange,
monoclonal: blue). 3D7 is shown in gray. The number of exon 1 sequences per sample, estimated from the counts of extracted exon 1 sequences are
listed on the bottom (see “Methods”)
Fig. 3 Overview of the ETHA algorithm for reconstructing exon 1 sequences: Illumina and PacBio sequencing data are both used in conjunction
with previously characterized exon 1 sequences from VarDom [13] as data inputs for reconstructing exon 1 sequences in clinical whole-genome
assemblies. Pacbio data are assembled and exon 1 ends are identified by mapping known exon 1 sequences from VarDom onto the assembly
(steps 1 and 2). Illumina data corresponding to var genes are identified by finding 71 bp segments (71mers) containing var splice site sequences
at the end of exon 1 in the assembly and iteratively following possible continuations (new trusted 71mers overlapping previously identified var
71mers by 70 bp) within the Illumina data (steps 3 and 4). This process is extended until a start methionine is reached (step 4). This k-mer walk is
repeated in the opposite direction, now from the start methionine to the intron. They are then assembled by generating all possible paths within
the de Bruijn graph of 71mers (step 5) and reconciled with the whole-genome assembly by choosing those paths which align best with the
whole-genome assembly (steps 6–8). Data inputs in white; processes are in gray. See “Methods” for additional details
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those ending with a known boundary sequence between
exon 1 and the intron were judged to include an end.
Those with neither were considered internal fragments
and those with both were considered complete exon 1
sequences. The median length of complete ETHA-
reconstructed exon 1 sequences in each sample was
much more similar to Pf3D7 and length variation was
far lower than that of sequences extracted by the original
method (Fig. 2; Additional file 1: Table S4). Since ETHA
includes redundancy reduction steps that will remove
nearly identical copies likely to result from sequencing
error, the number of complete sequences reconstructed
with ETHA is less than what was found with the exon 1
sequences extracted directly from the assemblies, and
the total cumulative length of all ETHA exon 1 se-
quences was closer to what was expected (Additional file
1: Table S5). Finally, the estimated number of copies re-
covered by ETHA, which can be inferred from the sum
of complete elements plus the largest of either the num-
ber of exon 1 start or end sequences (Additional file 1:
Table S5), is also closer to number of complete elements
in a genome than the number of var sequences extracted
directly from each assembly.
Validation of ETHA using NF54
To confirm that ETHA is indeed recovering true and ac-
curate var exon 1 sequences, we simulated the sequen-
cing, assembly and var sequence recovery process used
above for the 12 Malian clinical samples now using the
P. falciparum isolate NF54. NF54 is the isolate from
which the reference 3D7 was cloned [35]; therefore, any
var exon 1 sequences present in NF54 should be very
similar to those in the 3D7 genome. Indeed, this was
confirmed with the generation of a high-quality PacBio-
based whole-genome assembly of NF54, in which each
of the 61 3D7 vars was present in one intact piece. We
found no evidence in the NF54 assembly of extra var
sequences relative to the original 3D7 assembly, as
recently reported in a new PacBio-based 3D7 assembly
[21]. The only difference detected between the NF54
and original 3D7 assemblies across the 61 genes was one
small indel. The simulation was conducted by subsamp-
ling NF54 Illumina and PacBio reads such that the quality
metrics for the data used to create the assembly and the
ETHA pipeline input were on the low end of the Malian
samples, in an attempt to replicate the relatively poor
quality of the sequence data generated from the clinical
samples (see “Methods”) (Additional file 1: Table S3).
To assess sensitivity, specificity, accuracy, and contiguity
of the ETHA algorithm, exon 1 sequences were extracted
directly from the simulated NF54 assembly and also re-
constructed with ETHA, as done before for the Malian
clinical samples, and aligned to the known exon 1 se-
quences in the 3D7 reference. Overall, the ETHA output
can be characterized as having very high accuracy and
specificity at some cost to contiguity and sensitivity, while
the direct extractions were quite sensitive and contiguous
but at a cost to specificity and accuracy. ETHA output se-
quences covered 88.4% of the cumulative length of 3D7
var exon 1 sequences with alignments of at least 500 bp
and 100% identity. Lowering the identity threshold to 90%
identity increased the coverage only slightly to 92.8% and
lowering it further to 80% achieved only 93.6% coverage.
By contrast, the sequences extracted directly from the as-
sembly covered only 17.2% of the cumulative length of the
reference at 100% identity, but lowering the threshold to
90% identity increased coverage to 97.3% and lowering it
further to 80% achieved 97.8% coverage.
We also calculated coverage and percent identity for
the single best match between the two sources. For the
ETHA output, 38 of the 61 reference 3D7 exon 1 se-
quences were covered completely by a single match to
reconstructed sequence, all of these with 100% identity.
For the sequences extracted directly, only one reference
exon 1 was covered completely with 100% identity, but a
total of 53 of the 61 were covered completely at lower
identities (mean identity of 99.91%, range of 99.58–
99.98%). The high number of complete (if not 100% ac-
curate) exon 1 sequences extracted directly was most
likely facilitated by the nature of the NF54 simulated
sample that could not be degraded sufficiently to resem-
ble true clinical data (likely due to the difference be-
tween clinical and cultured parasite genetic material and
the longer reads from the updated PacBio chemistry
used to sequence NF54; see “Methods”). The ETHA
output’s low number of completely covered reference
3D7 exon 1 sequences likely reflects ETHA's conser-
vative nature, which by design will not merge two
pieces of sequences unless they are identical across
the overlapping region.
Validation of ETHA using long-range targeted PCR with
PacBio sequencing of var2csa
A second validation of the ETHA output was done by
sequencing var2csa with PacBio to compare the PCR
amplicon-based sequence to the sequence reconstructed
by ETHA. PCR primers spanning the UPS and ATS were
used to amplify the extracellular portion of var2csa,
corresponding to an amplicon around 10 Kb, and
then sequence it with PacBio using P6-C4 chemistry
(see “Methods”). For all except two samples (397_1
and 398_1), the var2csa gene was successfully ampli-
fied and sequenced. The ten amplicons were pooled
before sequencing with PacBio.
We assembled the PacBio reads with PacBio’s HGAP
assembler and further corrected the results using Pilon,
with the corresponding Illumina reads [36]. Three of the
ten samples (309_1, 366_1, and 383_1) had very low
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PCR amplicon product and did not yield the desired
amount (394.94 ng) to generate an equimolar ten-
sample amplicon pool before sequencing. Therefore, the
number of PacBio reads for these samples was insuffi-
cient to generate a reliable PacBio consensus amplicon
sequence. Of the remaining samples, two (318_1 and
377_1) failed to yield high-quality assemblies; for the last
five samples, we obtained a single high-confidence con-
tig assembly, thus providing an independent source
against which to assess the accuracy of the ETHA pipe-
line. In four of these five samples (303_1, 326_1, 327_1,
and 365_1), the assembled amplicon sequence corre-
sponding to exon 1 was 100% identical, end to end, to
the output of the ETHA pipeline, while the fifth (58_1)
differed by 11 nucleotides from the ETHA output, corre-
sponding to 99.87% identity. In each of the five samples,
the most similar var2csa-like sequence extracted directly
from the whole-genome assembly differed considerably
from the assembled amplicon, with differences in the
range of 6–2750 nucleotides (median = 287 bp). This val-
idation exercise provides further evidence that ETHA
produces sequences of higher accuracy than those ob-
tained using standard bioinformatic approaches to ex-
tract sequences directly from a default, low coverage
PacBio assembly.
As a positive control for this validation approach,
we also amplified and PacBio-sequenced the exon 1
of var2csa from the 3D7 isolate. The sequence
obtained was 100% identical to that in the published
3D7 genome assembly.
Subfamily composition
The upstream regions of var genes have previously been
classified into four UPS classes, namely UPSA, UPSB,
UPSC, and UPSE, which correspond to various chromo-
somal locations and clinical phenotypes [13]. UPSA
(associated with longer var genes) and UPSB (the most
common) tend to be sub-telomeric, whereas UPSC is lo-
cated centrally on chromosomes. UPSE is associated
only with var2csa. To determine if the var genes recon-
structed from the 12 clinical samples shared a similar
promoter breakdown, we extracted 2100 bp-long
segments upstream of each exon 1 found in the whole-
genome assemblies of the 12 Malian samples, and classi-
fied these by sequence similarity to the four UPS classes
(see “Methods”). As has been observed in other ge-
nomes, UPSB was the most common UPS class for each
of the clinical samples (Fig. 4). While previous work
found a similar number of UPSA and UPSC classes in a
parasite genome [13], UPSA tended to be more numer-
ous than UPSC in the 12 Malian clinical isolates studied
here. As expected, UPSE-like sequences were present at
very low numbers in each sample. Five samples had be-
tween two to four UPSE copies, half of the samples had
a single UPSE copy, and none were found in sample
318_1. In contrast, sample 377_1 had 15 UPSE-like se-
quences. The large number of UPSE sequences relative
to the four var2csa genes reconstructed with ETHA
from the 377_1 assembly likely stems from redundancy
in these low coverage PacBio assemblies and sample
polyclonality.
Structural characterization of var2csa and other vars
using VarDom
All ETHA exon 1 sequences were characterized and an-
notated using the VarDom server ([13]; www.cbs.dtu.dk/
services/VarDom/) (see “Methods”). Briefly, the exon 1
genomic sequences were used to predict open reading
frames (ORF); the resulting ORFs were translated into
protein sequences and submitted to VarDom for domain
prediction. The output files were parsed with custom
Python and Perl scripts to extract domain coordinates
and determine protein domain organization. The overall
domain organization was consistent between the sam-
ples (Fig. 5; Additional file 3: Figure S1), and similar to the
var composition in the 3D7 reference genome, with NTS-
DBLα-CIDRα-DBLδ-CIDRβ being the most frequent
arrangement and NTS-DBLα-CIDRα-DBLδ-CIDRγ the
second most common domain architecture. While this
domain architecture was conserved, individual PfEMP1
sequences were highly polymorphic. The most conserved
vars from the repertoire were var1, var3, and var2csa. Ac-
cording to the structural characterization of all samples,
var1, var3, and var2csa variants were present in nine,
seven, and 12 samples, respectively. Complete or nearly
complete var2csa exon 1 sequences were recovered from
all 12 samples, with some samples having more than one
var2csa sequence, providing cross-validation of the output
of the ETHA algorithm. Each sample possessed a similar
distribution frequency of constituent domains in these
three most widespread vars as the 3D7 isolate. The most
common domain found in each sequence was DBLα
(Additional file 1: Table S6).
PfEMP1s play an important role in malaria pathogen-
esis by mediating the binding of infected erythrocytes to
specific host receptors in different organs. Particular clin-
ical features have been associated with specific domains or
the combination of two or more domains defined as do-
main cassettes (DC). In particular, the expression of DC8
and DC13 has been associated with severe malaria [37].
Previously, DC8 was found in six of seven genomes from
different continents, while DC13 was found in five of
these genomes [13]. The reference 3D7 genome lacks
DC8. To identify these domain cassettes in our dataset,
we reconstructed phylogenetic trees using amino acid
sequence of domains from ETHA-reconstructed exon 1
sequences as well as amino acid sequences of known
DC13 and DC8 domain cassettes. Both domain cassettes
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were identified in 11 samples at least once (Additional file
3: Figures S2 and S3). Samples 58_1 and 397_1 had more
than one DC8 (paired domains). We detected neither
DC8 nor DC13 in sample 318. These results suggest that
differences in clinical outcome may be the result of vari-
ation in var expression and/or host immunity, instead of
being directly related to domain composition of the var
complement in the genome. These findings may also be
explained by other factors such as the timing of sample
collection, the possibility that the DC8s and DC13s
sequenced in these samples differ, in some critical
way, from DC8s and DC13s that have been associated
with severe malaria, or that these uncomplicated mal-
aria infections could have progressed to severe infec-
tions if left untreated.
Genetic diversity of var2csa and other vars
To characterize the diversity of var repertoires, average
amino acid identity was calculated for each domain of
the major DBL and CIDR classes, as well as the entire
exon 1 region of var2csa. Among a sample of vars
obtained from a collection of isolates from around the
globe, amino acid sequence identity of individual
domains was in the range of 30–92% [13]. The DBLε
(31% shared amino acid identity) and CIDRα domain
(30% shared amino acid identity) classes were the most
heterogeneous domains, whereas DBLβ and CIDRδ were
relatively more conserved, with 43% and 55% shared amino
acid identity, respectively (Additional file 1: Table S7).
Remarkably, both the relative sequence conservation
among domains and the range of amino acid sequence
identity observed among 12 Malian samples are essentially
identical to global isolates (Additional file 1: Table S7). We
also confirmed that VAR1 and VAR3 were among the most
conserved vars, with 67% and 87% shared amino acid iden-
tity, respectively. The high level of conservation of these
two proteins among parasites suggests particular—and as
yet undiscovered—niches in malaria pathogenesis that
warrant further investigation.
The genetic variation among VAR2CSA proteins is
particularly pertinent to the development of a pregnancy-
associated malaria vaccine. We identified and character-
ized the genetic diversity among the 19 different var2csa
sequences found in the 12 Malian samples. The average
shared amino acid sequence identity among these se-
quences was 79%. Sequence identity within the individual
Fig. 4 Subfamily composition of recovered ETHA exon 1 sequences: relative frequencies of each UPS class (UPSB in red, UPSA in green, UPSC in
orange, and UPSE in purple) for each of the 12 Malian samples, compared to the frequencies found by Rask et al. [13]
Fig. 5 Relative distribution of constitutive domains. Relative domain frequencies compared to the reference 3D7
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constituent domains ranged from 62% (DBLε10) to 92%
(DBLεpam4). DBLεpam4 was the most homogeneous do-
main, followed by DBLεpam5 and DBLpam3, both with
89% amino acid sequence identity (Additional file 1: Table
S7). The ID1–ID2a region of the VAR2CSA protein, which
contains the motif that binds the CSA binding region, is
the target of current efforts to develop a vaccine against
malaria in pregnancy. The average amino acid sequence
identity for this region was 74%, suggesting that it has
considerable heterogeneity even among parasites from
a single West African village. In addition, all 19
Malian ID1-ID2a sequences were unique.
To determine the relatedness among var2csa se-
quences from parasites collected in different geographic
locations, Malian sequences were aligned and compared
to var2csa sequences retrieved from the VarDom data-
base, which were obtained from parasites from across
the globe. A principal component analysis revealed that
var2csa sequences from Mali did not form a distinct
cluster; instead, Malian samples displayed a large range
of genetic diversity in the principal component analysis
(PCA) (Fig. 6a). Supporting this conclusion, phylogenetic
analyses showed Malian var2csa sequences not to be
monophyletic; in fact, several Malian sequences were
more closely related to var2csas from other continents
than they were to other Malian samples (Fig. 6b). The
phylogenetic network was reconstructed to account
for recombination, since recombination events were
detected in the data, both among Malian samples and
between these and other samples (Additional file 3:
Figure S4). An analysis under the assumption of no
recombination differed slightly in topology but still
showed Malian samples to be polyphyletic in the net-
work (Additional file 3: Figure S5). These results,
taken together, suggest that VAR2CSA sequences are
not structured according to geography, supporting the
idea that a VAR2CSA-based vaccine based on a num-
ber of strains within a region would still capture con-
siderable global var2csa sequence diversity.
Despite the tremendous variation among var2csa
sequences from a single Malian village, two VAR2CSA
C-terminal extracellular domains, DBLεpam4 and DBLε-
pam5, were remarkably conserved among these isolates.
In a recent study using the 3D7 VAR2CSA variant [38],
sera from multigravid women from Mali recognized a
fragment containing these two domains to a greater extent
than sera from nulliparous women, men, and children.
Other studies have also shown that these domains were
targets of maternal antibodies [39–41]. Our results suggest
that the high sequence conservation of the extracellular
C-terminal makes it a potential target for a subunit vac-
cine. Immune responses and allele-specific immunogen-
icity against different variants of these domains are
important to characterize, as previous studies suggest that
a repertoire of antibodies from women recognize both































Fig. 6 Sequence similarity among var2csa elements. a PCA of reconstructed and known var2csa exon 1 amino acid sequences: 19 var2csa
sequences reconstructed from the 12 Malian samples were aligned to VarDom var2csa sequences and Euclidian distance matrix generated from
the multiple alignment was used to plot the PCA. The sequences are colored based on their origin. 3D7, FCR3/IT4 (Gambia), HB3 (Honduras), Dd2
(Indochina), PFCLIN (Ghana), IGH (India), RAJ116 (India), AAQ73930 (Malayan Camp), and NHP (Plasmodium reichenowi, a Non-Human Primate
parasite var2csa). b Neighbor net of the reconstructed var2csa exon 1 nucleotide sequences based on uncorrected p-distances. The network is
inferred from the 19 var2csa sequences reconstructed from the 12 Malian samples and 11 var2csa sequences from the VarDom database multiple
alignments. The sequences are color-coded based on their origin as in Fig. 6a
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Conclusions
Sequence analysis of PfEMP1s from clinical isolates has
the potential to provide insights into malaria pathogen-
esis and vaccine design. Challenges in sequencing var
genes from clinical isolates have limited our understand-
ing of P. falciparum pathogenesis and ability to develop
interventions focused on this family of variant proteins.
We overcame these challenges by combining two se-
quencing technologies and developing and validating a
novel assembly algorithm. PacBio offered the advantage
of long reads, permitting assembly of vars, while Illu-
mina corrected the inherent sequencing errors associ-
ated with PacBio. ETHA is a novel algorithm for
reconstructing variable var exon 1 sequences from un-
finished, highly fragmented whole-genome assemblies
generated from clinical samples using PacBio and Illu-
mina data. This approach allowed us to accurately and
reproducibly reconstruct the sequence of full-length var
exon 1 from clinical isolates, in an automated fashion,
for the first time. While var sequences extracted directly
from the assemblies likely encompass almost all var
exon 1 sequences present in the sample, collection of se-
quences was both chimeric and redundant, and con-
tained sequencing errors. In contrast, ETHA removed
much of this duplication and reduced chimerism and se-
quencing errors, albeit with a slight cost in sensitivity
and contiguity, resulting in some fragmentation. The ac-
curacy of ETHA var reconstruction was validated using
several approaches, including the recovery of known
vars and the validation of the motif composition of
novel reconstructed vars.
This approach will provide valuable var sequence in-
formation for clinical infections, with the potential to vastly
expand the limited available sequence data from the field,
with associated clinical and epidemiological data. The pipe-
line described here can be adapted to other surface variant
proteins such as those encoded by the repetitive inter-
spersed family (rif) and the sub-telomeric variable open
reading frame (stevor) gene families, which have yet to be
sequenced from clinical infections.
This approach has some limitations. Sequence gen-
eration is dependent on the acquisition of adequate
quantities of venous blood (typically 3–5 mL) with a
sufficient parasitemia to guarantee enough parasite DNA
for at least a small insert PacBio library—here, a minimum
of 5000 parasites per microliter. In addition, the cost of
necessary next-generation sequencing may be prohibitive
for some projects. Finally, these blood samples required
leukocyte depletion in the field to reduce host DNA con-
tamination. New developments to deplete human DNA
from mixed host-parasite DNA samples, coupled with
sequencing technology advances to reduce costs and
improve sensitivity may soon overcome some of these
limitations.
Comparative sequence analysis showed that the reper-
toire of var genes found in a small number of isolates
from a single West African village was as variable as a
collection of isolates from different continents. However,
two immunogenic VAR2CSA C-terminal regions of exon
1 [38–40] exhibited considerable sequence conservation,
suggesting a potential target for vaccine development.
Additional var sequence data from different geographic
settings would serve to accurately determine epitope re-
gion variability. Such information would allow better
representation of PfEMP1 diversity on protein and
peptide microarrays used to assay malaria exposure and
immunity [38, 43–45].
We have shown that parasite sequences present in un-
complicated malaria infections included var2csas and
also var subtypes associated with severe malaria. Severity
of clinical infection was thus not dictated by the potential
for virulence of the var repertoire present in an infection.
The presence of DC8 and DC13 in the genomes of para-
sites in uncomplicated malaria infections contradicts a hy-
pothesis that severe malaria is caused by highly restricted,
virulent strains of P. falciparum [46], even though some
caveats to this point remain, as mentioned in “Results.”
Additional studies of host immunity, specific var gene
regulation and expression, and var gene subsets in differ-
ent clinical syndromes are needed to better understand
determinants of virulence.
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